(Q1)Jun 30, 2024 | (FY)Mar 31, 2024 | (Q4)Mar 31, 2024 | (Q3)Dec 31, 2023 | (Q2)Sep 30, 2023 | (Q1)Jun 30, 2023 | (FY)Mar 31, 2023 | (Q4)Mar 31, 2023 | (Q3)Dec 31, 2022 | (Q2)Sep 30, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow (Indirect Method) | ||||||||||
Cash flow from continuing operating activities | -12.24%-7.01M | -76.20%-29.44M | -89.68%-6.08M | -52.54%-7.52M | -94.43%-9.59M | -71.69%-6.25M | -162.79%-16.71M | -4.36%-3.21M | -184.35%-4.93M | -504.09%-4.93M |
Net income from continuing operations | -27.78%-10.4M | -139.52%-46.61M | -195.36%-15.57M | -220.55%-14.9M | -83.78%-8M | -56.90%-8.14M | -119.10%-19.46M | -113.65%-5.27M | -185.40%-4.65M | 5.05%-4.35M |
Operating gains losses | -45.95%65.89K | --154.11K | ---61.05K | --61.05K | --32.21K | -67.19%121.9K | ---- | ---- | ---- | ---- |
Depreciation and amortization | -24.27%46.05K | 10.85%261.75K | 9.89%64.93K | 16.02%70.58K | 9.62%65.42K | 7.58%60.81K | 703.44%236.13K | 101.05%59.09K | --60.83K | --59.68K |
Asset impairment expenditure | ---- | --0 | ---- | ---- | ---- | ---- | --24.13K | ---- | ---- | ---- |
Remuneration paid in stock | --1.25M | --6.31M | ---- | ---- | ---- | --0 | --0 | ---- | ---- | ---- |
Remuneration paid in stock | -78.83%221.5K | 157.06%7.91M | -15.48%678.13K | 1,679.19%6.21M | -102.29%-19.77K | -1.60%1.05M | --3.08M | --802.33K | --348.84K | --863.17K |
Other non cashItems | -64.09%163.06K | 264.08%552.36K | -98.47%1.59K | -79.20%2.23K | 1,553.26%94.52K | 1,346.51%454.03K | -96.98%151.71K | 0.71%103.91K | 114.35%10.7K | -99.89%5.72K |
Change In working capital | 685.52%1.64M | 368.19%1.98M | 72.59%2.5M | 196.90%1.04M | -55.15%-1.77M | 697.70%208.69K | 70.72%-738.74K | 296.43%1.45M | -3,404.20%-1.07M | 26.54%-1.14M |
-Change in receivables | 87.75%-7.21K | -632.99%-136.79K | 8.54%1.55M | -98.41%-941.29K | -32.31%-685.4K | 87.01%-58.85K | 98.92%-18.66K | 394.00%1.43M | 10.30%-474.41K | -37.24%-518.01K |
-Change in prepaid assets | 70.95%-130.24K | 159.58%648.33K | 460.36%436.54K | 347.44%809.22K | 43.49%-149.18K | -19.24%-448.25K | -268.47%-1.09M | 53.52%-121.14K | -3,001.30%-327.03K | -324.03%-263.99K |
-Change in payables and accrued expense | 116.06%1.78M | 156.73%1.62M | 538.35%906.85K | 1,991.52%860.36K | -145.42%-973.84K | -11.54%822.33K | 413.24%629.34K | 233.23%142.06K | -135.83%-45.49K | 33.13%-396.8K |
-Change in other working capital | ---- | 44.13%-145.99K | ---393.34K | 237.60%312.34K | 3.84%41.54K | -43.35%-106.54K | 12.97%-261.32K | --0 | -163.05%-227K | 107.73%40K |
Cash from discontinued investing activities | ||||||||||
Operating cash flow | -12.24%-7.01M | -76.20%-29.44M | -89.68%-6.08M | -52.54%-7.52M | -94.43%-9.59M | -71.69%-6.25M | -162.79%-16.71M | -4.36%-3.21M | -184.35%-4.93M | -504.09%-4.93M |
Investing cash flow | ||||||||||
Cash flow from continuing investing activities | 7.32%-186.23K | -51.57%-1.26M | -59.16%-1.09M | -169.31%-50.23K | 4,480.98%90.07K | -67.43%-200.94K | -179.39%-828.47K | -325.05%-687.74K | 79.26%-18.65K | -100.16%-2.06K |
Net PPE purchase and sale | 50.52%-24.33K | -25.08%-185.16K | -229.13%-24.06K | -169.31%-50.23K | -2,900.34%-61.69K | 59.02%-49.18K | 41.19%-148.03K | 95.48%-7.31K | 79.26%-18.65K | ---2.06K |
Net other investing changes | -6.68%-161.89K | -57.34%-1.07M | ---- | ---- | ---- | ---151.76K | ---680.43K | ---- | ---- | ---- |
Cash from discontinued investing activities | ||||||||||
Investing cash flow | 7.32%-186.23K | -51.57%-1.26M | -59.16%-1.09M | -169.31%-50.23K | 4,480.98%90.07K | -67.43%-200.94K | -179.39%-828.47K | -325.05%-687.74K | 79.26%-18.65K | -100.16%-2.06K |
Financing cash flow | ||||||||||
Cash flow from continuing financing activities | 95.53%16.19M | 73.51%27.54M | -51.63%2.51M | 2,664.43%892.22K | 47.47%15.85M | 23,900.74%8.28M | 42.46%15.87M | 4,608.56%5.19M | -100.32%-34.79K | 89,671.30%10.75M |
Net issuance payments of debt | 22,395.49%8M | -65.25%1.88M | -64.09%1.98M | 11.91%-30.65K | 1.90%-34.13K | -3.10%-35.87K | 350.00%5.41M | 4,886.42%5.51M | 97.96%-34.79K | 92.88%-34.79K |
Net common stock issuance | -84.45%1.17M | 132.34%27.36M | 130.30%483.01K | --10.94M | -27.35%8.4M | --7.54M | -10.89%11.77M | -98.38%209.73K | --0 | --11.56M |
Proceeds from stock option exercised by employees | 835.72%7.31M | ---- | ---- | ---- | --9.25M | --780.79K | ---- | ---- | ---- | ---- |
Net other financing activities | ---284.51K | -29.71%-1.7M | 109.20%48.74K | --12.31K | ---- | ---- | -1,567.68%-1.31M | ---529.61K | --0 | ---- |
Cash from discontinued financing activities | ||||||||||
Financing cash flow | 95.53%16.19M | 73.51%27.54M | -51.63%2.51M | 2,664.43%892.22K | 47.47%15.85M | 23,900.74%8.28M | 42.46%15.87M | 4,608.56%5.19M | -100.32%-34.79K | 89,671.30%10.75M |
Net cash flow | ||||||||||
Beginning cash position | -79.70%892.73K | -31.97%4.4M | 86.30%5.72M | 55.41%12.4M | 132.90%6.22M | -31.97%4.4M | 641.89%6.46M | -68.82%3.07M | 663.34%7.98M | 372.87%2.67M |
Current changes in cash | 390.60%8.99M | -89.66%-3.16M | -459.79%-4.67M | -34.01%-6.68M | 9.25%6.36M | 148.33%1.83M | -128.56%-1.66M | 138.72%1.3M | -155.44%-4.98M | 1,085.35%5.82M |
Effect of exchange rate changes | -623.21%-87.51K | 13.55%-347.84K | -620.69%-161.16K | -96.59%2.65K | 65.26%-177.23K | -1,305.34%-12.1K | -71.80%-402.34K | 195.84%30.95K | 140.61%77.77K | -4,812.34%-510.2K |
End cash Position | 57.58%9.8M | -79.70%892.73K | -79.70%892.73K | 86.30%5.72M | 55.41%12.4M | 132.90%6.22M | -31.97%4.4M | -31.97%4.4M | -68.82%3.07M | 663.34%7.98M |
Free cash from | -11.75%-7.04M | -75.75%-29.62M | -90.00%-6.11M | -52.98%-7.57M | -95.60%-9.65M | -67.52%-6.3M | -155.02%-16.86M | 0.64%-3.21M | -171.36%-4.95M | -504.34%-4.93M |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
No Data